The imine residue [C N = 1.268 (3) Å ; conformation = E] is twisted [N-N-C-N = 87.8 (2) ] out of the plane (r.m.s. deviation = 0.016 Å ) of the central 1,2,4-triazole ring in the title compound, C 30 H 34 F 2 N 6 S. A small twist also occurs between the imine and terminal benzene rings [N-C-C-C = À169.8 (2) ]. The piperazine ring (chair conformation) occupies a position almost normal to the central plane [N-N-C-N = 87.8 (2) ]. In the crystal, the molecules are consolidated into a three-dimensional architecture via C-HÁ Á ÁS, C-HÁ Á Á andinteractions, the latter between centrosymmetrically related difluorobenzene rings [intercentroid distance = 3.9389 (18) Å ].
Related literature
For a related structure and background to the biological activity of adamantane derivatives, see: El-Emam et al. (2012) . For further synthetic details, see: Al-Omar et al. (2010) Table 1 Hydrogen-bond geometry (Å , ).
Cg1 is the centroid of the C25-C30 ring.
Symmetry codes: (i) Àx þ 3 2 ; y À 1 2 ; Àz þ 3 2 ; (ii) x þ 5 2 ; Ày þ 1 2 ; z þ 3 2 .
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 (Farrugia, 1997) and DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: publCIF (Westrip, 2010).
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Tiekink Comment
In continuation to our interest in the chemical and pharmacological properties of adamantane derivatives, and as part of on-going structural studies (El-Emam et al., 2012) , the title compound (I) was synthesized as potential chemotherapeutic agent (Al-Omar et al., 2010) .
In (I), the central 1,2,4-triazole ring (r.m.s. deviation = 0.016 Å) is twisted with respect to the adjacent imine bond (1.268 (3) Å; conformation = E) as seen in the value of the C13-N1-N2-C11 torsion angle of 148.49 (19)°. There is a small twist between the latter and the connected benzene ring with the N1-C13-C14-C15 torsion angle being -169.8
(2)°. The piperazine ring (chair conformation) projects nearly normal to the central plane [N3-N4-C20-N5 = 87.8
(2)°].
Molecules are consolidated in the crystal packing by a combination of C-H···S and C-H···π interactions, Table 1 , as well as weak π-π interactions between centrosymmetrically related C(14-C19) benzene rings [inter-centroid distance = 3.9389 (18) Å for 1 -x, 1 -y, 1 -z], Fig. 2 .
Experimental
A mixture of the 5-(adamantan-1-yl)-4-(2,6-difluorobenzylideneamino)-4H-1,2,4-triazole-3-thiol (347 mg, 1 mmol), 1phenylpiperazine (162 mg, 1 mmol) and 37% formaldehyde solution (0.5 ml), in ethanol (8 ml), was heated under reflux for 15 min. after which a clear solution was obtained. Stirring was continued for 12 h at room temperature and the mixture was allowed to stand overnight. Cold water (5 ml) was added and the mixture was stirred for a further 20 min.
The precipitated crude product was filtered, washed with water, dried, and crystallized from ethanol to yield 434 mg (79%) of the title compound (I) as crystals. M.pt: 424-426 K. Light yellow prisms were obtained by slow evaporation of 76, 112.19, 116.31, 119.88, 129.10, 133.27, 151.38, 152 .24 (Ar-C), 155.64, 161.06 (triazole C-5 & CH=N), 163.22 (C=S).
Refinement
Carbon-bound H-atoms were placed in calculated positions [C-H = 0.93 to 0.98 Å, U iso (H) = 1.2U eq (C)] and were included in the refinement in the riding model approximation. 
Computing details
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO (Agilent, 2012); data reduction: CrysAlis PRO (Agilent, 2012); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 (Farrugia, 1997) and DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: publCIF (Westrip, 2010).
Figure 1
The molecular structure of (I) showing displacement ellipsoids at the 35% probability level. supplementary materials sup-3 Acta Cryst. (2012) . E68, o2031
Figure 2
A view in projection down the b axis of the unit-cell contents for (I). The C-H···S, C-H···π and π-π interactions are shown as orange, purple and brown dashed lines, respectively. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
3-(Adamantan-1-yl)-4-[(E)-(2,6-difluorobenzylidene)amino]-1-[(4-phenylpiperazin-1-yl)methyl]-1H-1,2,4-

triazole-5(4H)-thione
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq S1 0.71076 ( (9) 0.0551 (9) 0.0104 (7) −0.0041 (7) −0.0122 (8) N2
0.0376 (7) 0.0450 (8) 0.0528 (9) 0.0048 (6) 0.0006 (6) −0.0087 (7) N3 0.0449 (8) 0.0433 (8) 0.0526 (9) 0.0020 (6) 0.0018 (7) −0.0036 (7) N4 0.0469 (8) 0.0469 (8) 0.0496 (9) −0.0021 (7) 0.0022 (7) −0.0059 (7) N5 0.0538 (9) 0.0519 (9) 0.0444 (8) −0.0070 (7) 0.0029 (7) −0.0015 (7) N6 0.0504 (9) 0.0468 (9) 0.0533 (9) −0.0008 (7) 0.0035 (7) −0.0014 (7) F1 0.0608 (9) 0.179 (2) 0.0605 (9) 0.0320 (10) 0.0098 (7 
